world clinic experi remestemcel-l underscor market potenti
invest summari reiter overweight rate price
target mesoblast morn compani host virtual
symposium give in-depth overview remestemcel-l data steroid
refractori acut graft versu host diseas sr-agvhd commerci
strategi addit dr prockop memori sloan ketter cancer center
mskcc discuss opinion drug base real-lif clinic experi
key conclus call physician posit experi
use remestemcel-l clinic practic competit market pediatr
patient small exist concern place treatment option
mesoblast prepar commerci launch part due uniqu
advantag observ commerci progress temcel japan
 life clinic experi check box highlight
recent jakafi market cover young approv
posit read-across mesoblast primarili due trial design similar
mesoblast initi target approv use pediatr
patient competit overlap patient age dr
prockop highlight jakafi concern side effect profil infect
edema cytopenia note patient mskcc consid
trial first receiv treatment physician discuss two
real world clinic experi use remestemcel-l patient achiev
complet respons day remark patient present
late stage gvhd typic demonstr lowest probabl
surviv accord maximum gvhd score dr prockop indic
impress safeti profil rapid respons remestemcel-l
practic
 comprehens commerci strategi base healthcor claim
analysi mesoblast highlight cost treat pediatr patient
vs adult believ estim market price
justifi due cost rel line
comp main driver higher pediatr cost patient
spend time hospit mesoblast anticip split
reimburs landscap outpati inpati
compani expect estim payer mix commerci
medicaid rest public insur follow potenti
pediatr launch futur plan could includ launch ex-u
target chronic gvhd sr-agvhd adult patient expect approv
peak sale million model pediatr
disclosur section may found page
price target deriv combin risk-adjust npv futur cash
flow mlc platform model attribut rang probabl success
rheumatoid arthriti steroid-refractori acut gvhd japan approv
estim combin probability-adjust fully-tax npv cash flow
worth billion price target
clinic trial risk similar clinic development-stag compani mesoblast
expos signific clinic trial risk could gener neg outcom although
data mlc platform promis futur studi may yield similar result
failur achiev statist signific result could affect time likelihood
approv mesoblast product candid respect indic addit mlc
safeti profil may maintain later-stag studi market broader
regulatori risk compani develop cell therapi mesoblast requir
demonstr consist product safeti efficaci standpoint fda may
deni approv requir addit studi review believ submiss
satisfactorili address safeti efficaci manufactur drug candid
said mesoblast could achiev advantag rmat design regen medicin
product could acceler develop timelin
commercial/competit risk mesoblast core patent estat expir creat
opportun competit entrant although believ mesoblast know-how patent
strategi could provid suffici barrier entri addit entrant could creat competit
price reduc mesoblast share address market
manufactur risk process manufactur cell therapi complex rigor
although know-how engin cell give mesoblast distinct advantag potenti
biolog analog process could contain risk lonza lonn cover
mesoblast manufactur partner announc complic manufactur facil
although setback affect mesoblast current clinic oper manufactur
issu futur could affect potenti commerci launch
financ risk report cash equival posit mesoblast million
mesoblast develop mesenchym lineag cell therapi treatment diseas signific unmet need mesoblast lead
candid remestemcel-l complet phase studi treatment pediatr steroid-refractori gvhd temcel approv
commerci japan steroid-refractori gvhd children adult addit mesoblast conduct three mid-to-late-
stage clinic trial mesenchym precursor cell line treatment chronic heart failur phase chronic lower back pain
phase rheumatoid arthriti phase
analyst primarili respons research report whose name appear front cover certifi view express
research report accur reflect person view subject secur issuer featur report ii part
research analyst compens directli indirectli relat specif recommend view express
research analyst report
lead co-manag cantor fitzgerald and/or affili act lead co-manag public offer equiti and/or debt secur mesoblast
ltd adr within last month
invest bank last month cantor fitzgerald and/or affili receiv compens invest bank servic last month
mesoblast ltd adr
invest bank next month cantor fitzgerald and/or affili expect receiv intend seek compens invest bank
servic within next three month compani referenc within report
cantor fitzgerald and/or affili market maker mesoblast ltd adr
cantor fitzgerald and/or affili market maker corpor
overweight/ow analyst expect stock total return stock price appreci plu dividend outperform rel analyst broadli
defin sector next month purpos calcul percentag subject compani within buy hold sell categori
cantor fitzgerald provid invest bank servic within previou month overweight rate equat buy rate
neutral analyst expect stock total return stock price appreci plu dividend perform line rel analyst broadli
defin sector next month purpos calcul percentag subject compani within buy hold sell categori
cantor fitzgerald provid invest bank servic within previou month neutral rate equat hold rate
underweight/uw analyst expect stock total return stock price appreci plu dividend under-perform rel analyst
broadli defin sector next month purpos calcul percentag subject compani within buy hold sell categori
cantor fitzgerald provid invest bank servic within previou month underweight rate equat sell rate
covered/nc cantor fitzgerald provid invest opinion provid research coverag stock
rated/nr current carri rate stock rate estim review nr rate equat overweight
neutral underweight rate thu count calcul percentag subject compani within three categori
cantor fitzgerald provid invest bank servic within previou month
report inform purpos base publicli avail data believ reliabl represent made data
accur complet opinion project contain herein reflect opinion date report subject chang pursuant
cantor fitzgerald polici author report share compani he/sh cover
cantor fitzgerald cantor fitzgerald logo trademark regist trademark cantor fitzgerald secur affili
countri trademark appear herein properti respect owner neither cantor fitzgerald secur affili
associ affili third parti
materi present sole institut commun meant view complet fundament analysi secur
materi may offer recommend strategi shorter term natur materi contain analysi may narrowli focus
may base either pure quantit model uniqu factor market supply/demand factor surround potenti market move
event make invest decis inform view one factor invest decis process past perform
taken indic guarante futur result
disclosur uk investor
materi approv distribut unit kingdom cantor fitzgerald europ cfe cfe authoris regul
conduct author fca believ inform materi upon inform base accur except
oblig rule fca guarante accuraci materi intend use elig counterparti profession
client fall within articl servic market act promot order gener invest
public none invest invest servic mention describ herein avail person particular
avail retail client defin rule fca
disclosur canadian institut investor
research report prepar analyst cantor fitzgerald co cantor fitzgerald canada corpor result report
prepar subject canadian disclosur requir cantor fitzgerald canada may distribut research report prepar affili
financi instrument discuss report may suitabl investor investor must make invest decis base
specif invest object past perform taken indic guarante futur perform price valu
incom financi instrument featur report rise well fall affect chang econom financi polit
factor financi instrument denomin currenc investor currenc chang exchang rate may advers affect price
valu incom deriv financi instrument investor effect assum currenc risk addit investor secur
adr whose valu affect currenc home market underli secur effect assum currenc risk
rate price target histori mesoblast ltd adr meso
initi overweight/ow buy neutral hold
underweight/uw sell sp specul buy nr rate drop
power bluematrix
rate price target histori incyt corpor
initi overweight/ow buy neutral hold
underweight/uw sell sp specul buy nr rate drop
power bluematrix
distribut ratings/invest bank servic ib
addit inform avail request copyright cantor fitzgerald
head healthcar research
